BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.

BrightGene Bio-Medical Technology Co., Ltd.

688166

CNE100003PR1

BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research, development and production of generic drugs and original new drugs. The Company's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The Company's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The Company mainly conducts its businesses in domestic and overseas markets.

Employees

1,208

Sector

Pharmaceuticals

Calendar

24/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.84CNY

Average target price

38.00CNY

Spread / Average Target

+52.98%

Consensus

Profit revisions

Estimate revisions

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 19/09/2024			5-day change	1st Jan Change
24.84 ^CNY	+3.80%		+2.69%	-29.03%

08-23	BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
08-02	BrightGene Gets Nod to Trial Salmeterol Fluticasone Inhalation Powder	MT

BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-22	CI
BrightGene Gets Nod to Trial Salmeterol Fluticasone Inhalation Powder	08-02	MT
China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7%	05-07	MT
BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3%	05-07	MT
BrightGene Bio-Medical Technology Co., Ltd. announced that it expects to receive CNY 499.999987 million in funding	05-05	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-27	CI
BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback announced on February 7, 2024, has closed with 363,461 shares, representing 0.09% for CNY 10.01 million.	04-18	CI
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	04-18	CI
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	04-01	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-25	CI
BrightGene Bio-Medical Technology Co., Ltd. announces an Equity Buyback for CNY 20 million worth of its shares.	02-06	CI
BrightGene Bio-Medical Technology Co., Ltd. authorizes a Buyback Plan.	02-05	CI
Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd.	01-28	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Chinese Regulator Issues Warning Against BrightGene Bio-Medical Chairman Over Weight Loss Claims	19/10/23	MT
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs	17/10/23	MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23	CI
BrightGene Bio-Medical Technology's Unit Gets Hospital's Approval for Diabetes Drug Trial	27/07/23	MT
Chinese Drug Regulator Certifies Two Drugs of BrightGene's Unit	06/07/23	MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
BrightGene Bio-Medical to Hike Investment in API Production Project to 500 Million Yuan	08/02/23	MT
Xinchuang Biomedical Technology Subsidiary Gets Nod to Hold Anti-Diabetes Drug Trial	30/12/22	MT
BrightGene Bio-Medical Technology Co., Ltd. announced that it has received CNY 226.613082 million in funding from Horizon Asset Management Co. Ltd., Shanghai Leitu Asset Management Co., Ltd. and other investors	20/11/22	CI
BrightGene Bio-Medical Technology Unit Gets Regulatory Approval For Anti-Inflammatory Drug Ingredient	18/11/22	MT

BrightGene Bio-Medical Technology Co., Ltd.

Equities

688166

CNE100003PR1

Pharmaceuticals

Latest news about BrightGene Bio-Medical Technology Co., Ltd.

Chart BrightGene Bio-Medical Technology Co., Ltd.

Company Profile

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise